** Alphamab Oncology 9966.HK jumps 15.2% to HK$12.1, highest since November 2023

** Stock set for biggest one-day pct gain since May 21

** Alphamab says new drug application for KN026 combined with chemotherapy to treat patients with metastatic gastric or gastroesophageal junction cancer accepted by China's National Medical Products Administration (NMPA)

** Adds KN026 co-developed with Shanghai JMT-Bio Technology - subsidiary of CSPC Pharmaceutical Group 1093.HK; multiple phase III clinical trials underway in China

** Shares of CSPC climb 4.2% to HK$10.54

** YTD, Alphamab shares surges 242.3%, CSPC stock soars 113.3%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))